论文部分内容阅读
Objectives To investigate the concentration of plasma plasminogen activator inhibitor-1 and the promoter-844G-A substitution,-675 4G/SG polymorphism in patients with CHD and control,Methods 293 patients with CHD (UAP group andAMIgroup) and 173 human in health (control group)were studied.Plasma PAI-1 antigen was measured by ELISA.